NSCLC
55 programs · 55 companies
Programs
55
Companies
55
Trials
44
MOAs
37
EGFRiCDK2iSOS1iPRMT5iCGRPantPARPiCD47iBTKiIL-13iBCMA ADC
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Phase 2 | KIF18A | ||
| AZN-6870 | Phase 2/3 | EGFR | ||
| DSN-6862 | Preclinical | IL-23 | ||
| REG-647 | Preclinical | SMN2 | ||
| VRT-1891 | Phase 1 | KRASG12C | ||
| Sematapinarof | NDA/BLA | VEGF | ||
| UTH-9370 | NDA/BLA | TIGIT | ||
| Bemavorutinib | Phase 1/2 | WEE1 | ||
| Datocilimab | Phase 1 | TYK2 | ||
| Voxabrutinib | Phase 1/2 | EZH2 | ||
| Lisozanubrutinib | NDA/BLA | CD20 | ||
| Polasertib | Phase 1 | RET | ||
| Voxanaritide | Approved | SGLT2 | ||
| TLX-9433 | Phase 2 | KRASG12D | ||
| BHC-6524 | Approved | Cl18.2 | ||
| SAM-IIT-936 | Phase 3 | PSMA | ||
| Zanulemzoparlimab | Phase 1 | JAK2 | ||
| AVX-9264 | Phase 2/3 | CD20 | ||
| MBX-6478 | Phase 1/2 | MET | ||
| Fixaratamab | Phase 1/2 | PD-L1 | ||
| Bemacapivasertib | Phase 2 | IL-23 | ||
| Bemasertib | Phase 1 | PLK4 | ||
| Motafutibatinib | Preclinical | AuroraA | ||
| MED-3942 | Phase 2 | Tau | ||
| Elranesiran | Phase 1 | RET | ||
| NOR-1166 | Phase 1 | WRN | ||
| Sovazasiran | Phase 3 | FcRn | ||
| Pemitenlimab | Phase 3 | Tau | ||
| MIR-6154 | Phase 2 | WEE1 | ||
| Elrasertib | Phase 3 | TIGIT | ||
| Riluzasiran | Phase 2/3 | SHP2 | ||
| PCV-2362 | Phase 1 | TIGIT | ||
| NTR-7700 | Phase 1/2 | Nectin-4 | ||
| Capicilimab | Phase 2/3 | MET | ||
| Fixacagene | Preclinical | PI3Kα | ||
| Tixatuximab | Phase 3 | CD123 | ||
| Zoriosocimab | Phase 3 | MET | ||
| 618-7080 | Phase 2 | MDM2 | ||
| Sematuximab | Phase 2/3 | FXIa | ||
| BEL-9345 | NDA/BLA | CD38 | ||
| 654-2851 | Preclinical | CD123 | ||
| SMM-5951 | Phase 2/3 | LAG-3 | ||
| Sotomavacamten | NDA/BLA | TIM-3 | ||
| Kemazumab | Approved | BCMA | ||
| DIV-3233 | Phase 2/3 | PD-L1 | ||
| APN-1617 | Phase 2 | PLK4 | ||
| RUI-IIT-540 | Approved | TIM-3 | ||
| 002-6973 | Approved | MET | ||
| 002-5533 | Phase 2/3 | AuroraA | ||
| Elrasacituzumab | NDA/BLA | TNFα | ||
| Zanufotisoran | Approved | PLK4 | ||
| Olpazumab | Phase 1/2 | EGFR | ||
| Lisosertib | Phase 1 | BTK | ||
| DER-8696 | Phase 1/2 | EGFR | ||
| Kemamavacamten | Phase 3 | B7-H3 |
Trials (44)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07591896 | AZN-6870 | Phase 2/3 | Terminated |
| NCT05867599 | AZN-6870 | Phase 2/3 | Not yet recr... |
| NCT07636934 | Sematapinarof | NDA/BLA | Completed |
| NCT05336465 | UTH-9370 | NDA/BLA | Active |
| NCT06682025 | Voxabrutinib | Phase 1/2 | Active |
| NCT03153021 | Voxanaritide | Approved | Recruiting |
| NCT03181860 | TLX-9433 | Phase 2 | Recruiting |
| NCT04373684 | TLX-9433 | Phase 2 | Not yet recr... |
| NCT06870343 | SAM-IIT-936 | Phase 3 | Completed |
| NCT04855461 | Zanulemzoparlimab | Phase 1 | Not yet recr... |
| NCT05977181 | AVX-9264 | Phase 2/3 | Completed |
| NCT04053110 | Bemasertib | Phase 1 | Active |
| NCT03741438 | Bemasertib | Phase 1 | Completed |
| NCT06875616 | Motafutibatinib | Preclinical | Recruiting |
| NCT05729045 | MED-3942 | Phase 2 | Terminated |
| NCT05285525 | MED-3942 | Phase 2 | Not yet recr... |
| NCT03468933 | Elranesiran | Phase 1 | Active |
| NCT08706988 | NOR-1166 | Phase 1 | Not yet recr... |
| NCT05500765 | Sovazasiran | Phase 3 | Not yet recr... |
| NCT05340872 | Sovazasiran | Phase 3 | Recruiting |